ACE inhibitors and mineralocorticoid receptor blockade in patients with congestive heart failure

Current Diabetes Reports

Volumn 5, Issue 1, 2005, Pages 36-40

  Funder, John W ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; FUROSEMIDE; HORMONE RECEPTOR BLOCKING AGENT; KETOCONAZOLE; MINERALOCORTICOID RECEPTOR; PLACEBO; POTASSIUM; SPIRONOLACTONE; TRANDOLAPRIL;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CREATININE CLEARANCE; DIABETIC HYPERTENSION; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; FOOD DRUG INTERACTION; GYNECOMASTIA; HEART PROTECTION; HUMAN; HYPERKALEMIA; KIDNEY DYSFUNCTION; LOW DRUG DOSE; NONHUMAN; RECEPTOR BLOCKING; REVIEW; SUPPLEMENTATION; SURVIVAL; TREATMENT OUTCOME;

EID: 14044270116     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-005-0065-5     Document Type: Review

References (20)

1. Brilla CC, Weber KT: Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992, 120: 93-901.
2. Ikram H, Webster MWI, Nicholls MG, et al.: Combined spironolactone and converting enzyme inhibitor therapy for refractory heart failure. Aust N Z J Med 1986, 34:57-60.
3. Dahlstrom U, Karlsson E: Captopril and spironolactone therapy in patients with refractory congestive heart failure. Am J Cardiol 1993, 71:29A-33A.
4. Barr CS, Lang CC, Hanson J, et al.: Effect of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995, 76:1259-1265.
5. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709-717.
6. Zannad F, Alla F, Dousset B, et al.: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000, 102:2700-2706.
7. Krum H, Nolly H, Workman D, et al.: Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients Hypertension 2002, 40:117-123.
8. Epstein M, Buckalew V, Martinez FJ, et al.: Antiproteinuric efficacy of eplerenone, enalapril and eplerenone/enalapril combination in diabetic hypertensives with microalbuminuria [abstract]. Am J Hypertens 2002, 15(suppl 1):24A.
9. Pitt B, Reichek N, Willenbrock R, et al.: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003, 108: 831-1838.
10. Bauersachs J, Heck M, Fraccarollo D, et al.: Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction. J Am Coll Cardiol 2002, 39:351-358.
11. Schafer A, Fraccarollo D, Hildemann SK, et al.: Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. Cardiovasc Res 2003, 58:655-662.
12. Farquharson CA, Struthers AD: Spironolactone increases nitric oxide bioavailability improves endothelial vasodilator function, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101: 94-597.
13. Abiose AK, Mansoor GA, Barry M, et al.: Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy. Am J Cardiol 2004, 93:1564-1566.
14. Schafer A, Fraccarollo D, Hildemann SK, et al.: Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition. Thromb Haemost 2003, 89:1024-1030.
15. Pitt B, Remme W, Zarnnad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
16. Blaustein DA, Schwenk MH: Letter to Editor: Eplerenone in patients with left ventricular dysfunction. N Engl J Med 2003, 349:88-89.
17. Sica DA: Hyperkalemia, congestive heart failure, and aldosterone receptor antagonism. Congest Heart Fail 2003, 9: 24-229.
18. Levy D, Rocha R, Funder JW: Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab 2004, 89:2736-2740.
19. Bozkurt B, Agoston I, Knowlton AA: Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003, 41:211-214.
20. Funder JW: Is aldosterone bad for the heart? Trends Endocrinol Metab 2004, 15:139-142.